AstraZeneca pays $630m to get full control of AbelZeta CAR-T AstraZeneca's push into CAR-T therapies for cancer has continued with an agreement to take full control of C-CAR031 from Chinese partner AbelZeta.

#AstraZeneca's push into #CART therapies for #cancer has continued with an agreement to take full control of C-CAR031, an #antiGPC3 therapy for #solidtumours, from #AbelZeta.

pharmaphorum.com/news/astraze...